A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe

Registry ID

EUCTR2020-001449-38

Source registry

EUCTR

Status

GB - no longer in EU/EEA

Phase

PHASE3

Sponsor

Chelsea and Westminster Hospital NHS Foundation Trust

Start date

2020-04-29

Last update

2026-08-16

Conditions

• COVID-19 Infection

Summary

To determine whether early intervention with either a combination of hydroxychloroquine, azithromycin and zinc or favipirivir improves time to significant improvement in clinical status.

Locations

• , , UK

Related clinical trials

• A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
• The Impact of COVID-19 on Pulmonary Procedures
• Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce
• The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
• Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
• Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

View on source registry